This systematic review and meta‐analyses attempted to understand the differences among different FLT3 inhibitors in general and between type 1 and type 2 FLT3 inhibitors in treating R/R AML and HR‐MDS patients. This evidence concerns the gene FLT3 and myelodysplastic syndrome.